Toray Advanced Composites and Joby Aviation Finalize a Long-Term Supply Agreement
Toray Advanced Composites announces that it has completed a long-term supply agreement with Joby Aviation for the composite material used for its aircraft. The California-based aircraft company will use Toray’s carbon fiber composite materials to bring fast, affordable, and zero-emissions aerial ridesharing to global communities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201208005035/en/
Shown here: In a Joby Aviation composites lab an automated fiber placement (AFP) machine applies composite material used to fabricate aircraft parts. High performance composite materials are essential in making the Joby aircraft lightweight. Location: Joby's Marina, CA facility is the future of manufacturing for Joby. Photographer: John Kaemmerling
Electric aircraft require proven materials that have high-strength and are very lightweight. Carbon fiber composite materials provide the strength-to-weight ratio needed for electric aerospace applications in order to maximize the range and speed of the aircraft. Every aspect of Joby’s aircraft is being optimized for maximum utilization for urban transport and high-quality carbon fiber materials are a key component of achieving their goals. Joby selected Toray Advanced Composite materials due to their proven heritage of meeting mechanical and safety requirements in aerospace and high-performance automotive applications.
JoeBen Bevirt, Founder and CEO, Joby Aviation, said: "Toray’s prepreg carbon fiber systems provide unparalleled specific strength and toughness, which have enabled Joby to develop aircraft with unprecedented capabilities. We are incredibly proud to be working with Toray as we certify this aircraft, and look forward to building a long-lasting partnership."
Joby will operate an affordable, quiet, and clean transportation service, using the revolutionary all-electric, vertical take-off and landing aircraft it has spent the last decade developing. With a range of up to 150 miles and a top speed of 200 mph, the vehicle and the service has the potential to make a significant difference to the lives of travelers. Carbon fiber materials are used throughout the vehicle structure, propulsion systems, and interior components.
“We are very pleased to have finalized this important supply agreement with Joby Aviation, a pioneer in the development of the eVTOL,” says Mr. Toshiyuki Kondo, CEO, Toray Advanced Composites. “As children, we dreamed of being able to fly to a destination in a fraction of the time it would take to drive. That is no longer a fantasy. The electric air taxi is becoming a reality and we at Toray are perfectly positioned to meet the industry’s needs today and in the future. It’s a very exciting time.”
Joby Aviation has spent more than a decade developing its aircraft and plans to bring it into commercial operation as early as 2023. By combining years of development with a world-class team and now a leading carbon fiber composite supplier, Joby is well-positioned to deliver on the promise of aerial ridesharing.
About Joby Aviation
Joby Aviation is a California-based aerospace company that is developing and commercializing all-electric vertical take-off and landing aircraft (designated by the FAA as the S4) to enable the deployment of fast, quiet, and affordable air taxi services. The company’s mission is to deliver people to their destination five times faster than driving would, reduce urban congestion, and accelerate the shift to sustainable modes of transit. Founded in 2009, Joby pioneered the development of eVTOL aircraft and has offices in Santa Cruz, San Carlos, and Marina, California. Find more information at http://www.jobyaviation.com.
About Toray Advanced Composites
Toray Advanced Composites is a leader in the development and production of advanced thermoplastic and thermoset composite materials. The broad product portfolio is incorporated in high performance products for aerospace, space, communications, automotive, consumer, and industrial applications. Toray Advanced Composites has a long heritage of combining state-of-the-art materials technology with world-class technical expertise to deliver a unique customer-centric business model. Production and operation facilities are in North America, Europe, and Asia. Toray Advanced Composites is a subsidiary of the Toray Group. For more information visit, www.toraytac.com
©2020 Toray Advanced Composites. All trademarks are the property of Toray Industries Inc. unless otherwise stated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005035/en/
Contact information
Joby Aviation
Press contact:
Mojgan Khalili, press@joby.aero, 408-489-4015
Toray Advanced Composites
Media Inquiries (North America):
Johanna Beckmen, Director of Marketing USA
t +1 669-888-5416
e j.beckmen@toraytac-usa.com
Media Inquiries (Europe, Middle East):
Jenny Hodgson, Marketing Manager EMEA
t +44 1773 536966
e j.hodgson@toraytac-europe.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom